近期欧美有报道称，在接种 COVID-19 疫苗后出现急性心包炎病例系列。
A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States.
机构信息
First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Vaccine. 2021 Oct 29;39(45):6585-6590. doi: 10.1016/j.vaccine.2021.09.078. Epub 2021 Oct 5.
BACKGROUND
COVID-19 vaccines were efficacious and safe in clinical trials. We report nine events of acute pericarditis (AP) in eight patients following COVID-19 vaccination with BNT162b2 (6/9), AZD1222 (2/9) and mRNA-1273 (1/9).
METHODS
All patients were referred for AP temporally linked with COVID-19 vaccination. Chest pain was the most common clinical manifestation. Alternative etiologies were excluded upon thorough diagnostic work up. AP diagnosis was established according to ESC guidelines.
FINDINGS
Five events occurred after the first vaccine dose and four after the second. The mean age in this cohort was 65.8 ± 10.2 years and the men/women ratio 3/5. All events resolved without sequelae; two events were complicated by cardiac tamponade requiring emergent pericardial decompression. Hospitalization was required in four cases.
INTERPRETATION
Although causality cannot be firmly established, AP has emerged as a possible complication following COVID-19 vaccination. Further investigation is indispensable to fully characterize this new entity.
背景
COVID-19 疫苗在临床试验中具有疗效和安全性。我们报告了 8 例患者在接种 BNT162b2（6/9）、AZD1222（2/9）和 mRNA-1273（1/9）后出现 9 例急性心包炎（AP）事件。
方法
所有患者均因 COVID-19 疫苗接种与 AP 时间相关而被转诊。胸痛是最常见的临床表现。通过彻底的诊断性检查排除了其他病因。AP 的诊断依据 ESC 指南。
结果
5 例发生在第一剂疫苗后，4 例发生在第二剂疫苗后。该队列的平均年龄为 65.8±10.2 岁，男女比例为 3/5。所有事件均无后遗症消退；2 例事件并发心脏压塞，需要紧急心包减压。4 例需要住院治疗。
解释
虽然不能确定因果关系，但 AP 已成为 COVID-19 疫苗接种后的一种可能并发症。进一步的调查对于充分描述这一新实体是必不可少的。
Zotero 插件